Afternoon Update on Plandai Biotech (PLPL)

Plandai Biotechnology, Inc. PLPL
We’re sending out an update on PLPL this afternoon following this morning’s report. After trading as low as .55, the stock made its way back to .67, registering a 22% intraday gain in the process, and is currently holding support above the 50DMA.
In addition to an opportunity for a tidy profit during early trading, PLPL provided the public with a new press release that you can check out below. It eludes to an intellectual property licensing agreement, under the terms of which the company should be able to increase the effectiveness of its botanical extracts by a significant margin.

SEATTLE, WA, September 3, 2013 – (ACCESSWIRE) – Plandai Biotechnology, Inc. (PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has signed an exclusive agreement with North-West University in Potchefstroom, South Africa, that holds the patents and associated intellectual property associated with the entrapment of compounds in long-chain fatty acids-based nano- and micro-particles, known as Pheroid(R). Under the terms of the world license, Plandai has the exclusive right to use the Pheroid(R) technology with all Phytofare polyene-based extracts, which includes proprietary extracts of most botanical matter, for human and animal use. >>> FULL PR

Some links for those who may have missed this morning’s newsletter:
PLPL Report
PLPL Video Chart

Extended Watchlist:

Comments are closed.